Patrys antibody shows promise in blood cancers

Clinical stage biotechnology company Patrys has released an update on the development program for its anticancer product PAT-LM1. The company’s most recent laboratory experiments evaluated the efficacy of PAT-LM1 in blood cancers, including different types of leukaemias and lymphomas.

PAT-LM1 is a natural human IgM antibody that binds to a proprietary disease target, NONO, which is expressed on the surface of cancer cells but not on the surface of the healthy tissues. The product has already shown promise in preclinical development as a potential treatment for multiple types of cancer, including colon, lung, breast, ovary, pancreatic and various haematological cancers.

In the blood cancer experiments, PAT-LM1 showed very strong and specific binding to more than 90% of tested lymphoma cell lines and patient samples. It was able to induce cell death in mantle cell lymphoma and histiocytic lymphoma cells. It also bound specifically and strongly to some very rare lymphoma types, indicating that it may have broad therapeutic application covering the whole range of different lymphomas. 

“The results demonstrated in this preclinical work confirm the potential of PAT-LM1 as an effective therapy for a broad range of lymphomas,” said Patrys CEO Dr Marie Roskrow. “Currently we anticipate that this antibody will be moved into clinical trial at the University of Würzburg, where we will be working with the same clinicians who successfully executed the recent PAT-SM6 multiple myeloma trial.”

PAT-LM1 will be the second IgM antibody in Patrys’ pipeline to enter clinical development.